| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 14,281,212 | 1,681,915 | ||
| Prepaid expenses | 253,077 | 274,079 | ||
| Other current assets | 32 | 55,208 | ||
| Total current assets | 14,534,321 | 2,011,202 | ||
| Equipment, net of accumulated depreciation of 573,603 and 524,639 at september 30, 2025 and december 31, 2024, respectively | 429,344 | 473,215 | ||
| Total assets | 14,963,665 | 2,484,417 | ||
| Accounts payable | 3,693,115 | 3,314,839 | ||
| Accrued liabilities | 1,256,965 | 1,861,464 | ||
| Related party note | 5,725,267 | 5,506,346 | ||
| Other current liabilities | 2,758,207 | 2,480,916 | ||
| Total current liabilities | 13,433,554 | 13,163,565 | ||
| Related party note | 0 | 0 | ||
| Due to related parties | 15,043,093 | 14,510,167 | ||
| Common stock, par value 0.00001 per share 150,000,000 shares authorized 4,600,585 and 3,963,045 shares issued at september 30, 2025 and december 31, 2024, respectively | 46 | 40 | ||
| Additional paid-in capital | 141,252,978 | 126,716,146 | ||
| Accumulated other comprehensive loss | -692,114 | -719,318 | ||
| Accumulated deficit | -154,073,892 | -151,186,183 | ||
| Total stockholders' deficit | -13,512,982 | -25,189,315 | ||
| Total liabilities and stockholders' deficit | 14,963,665 | 2,484,417 | ||
MiNK Therapeutics, Inc. (INKT)
MiNK Therapeutics, Inc. (INKT)